CPT code 0483U: Gonorrhea resistance, gyrA S91F mutation2026 Medicare lab fee · Clinical Laboratory Fee Schedule
This proprietary molecular assay estimates fluoroquinolone resistance in gonorrhea from an oral, rectal, or vaginal swab by assessing a gyrA mutation.
Medicare pays $35.09 for 0483U under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$35.09
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2026
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 0483U covers
This proprietary assay evaluates the gyrA S91F point mutation in Neisseria gonorrhoeae and reports a probability of fluoroquinolone resistance from an oral, rectal, or vaginal swab. It addresses antimicrobial resistance, not whether gonorrhea is present. Clinicians may use the result when resistance information is relevant to treatment decisions. The molecular result is based on the mutation rather than growth-based susceptibility testing.
Report 0483U for the assay’s resistance-probability result; a gonorrhea detection test addresses the separate question of organism presence. Medicare pays 0483U only under the CLFS, at one national amount in every state and locality, without geographic or office/facility adjustment. The 2026 national CLFS amount is $35.09.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 0483U
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 0483U. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Not on the physician fee schedule
The physician fee schedule doesn’t list 0483U: Medicare pays the test only from the CLFS.
0483U on the lab fee schedule since 2024
0483U · CLFS 2026 Q4 (current)
$35.09
Unchanged since Jan 1, 2026
Every change on file
- Jan 1, 2026 · CLFS 2026 Q1MAC-priced → $35.09
9 quarterly CLFS releases on file, first CLFS 2024 Q4. A code missing from a quarter wasn’t on that release.
0483U compared with similar tests
- 87591Gonorrhea testAmplified DNA probe$35.09
- 87591 detects Neisseria gonorrhoeae by an amplified nucleic acid method. 0483U estimates fluoroquinolone resistance and does not serve as the organism-detection test.
- 87186Susceptibility testMicrodilution or agar dilution$8.65
- 87186 reports antimicrobial susceptibility testing. 0483U is a mutation-based assay that estimates fluoroquinolone resistance.
- 0484UM. genitalium resistanceMacrolide resistance probability$35.09
- 0484U evaluates a Mycoplasma genitalium 23S rRNA point mutation. 0483U evaluates a gyrA mutation associated with fluoroquinolone resistance in gonorrhea.
0483U billing questions
Which specimens are used for this assay?
The assay is described for oral, rectal, or vaginal swabs.
Does 0483U detect gonorrhea infection?
No. It reports a probability of fluoroquinolone resistance based on the gyrA S91F mutation; a gonorrhea detection test addresses whether the organism is present.
Can 0483U be reported with a gonorrhea NAAT?
A gonorrhea NAAT such as 87591 detects the organism, while 0483U evaluates resistance. They address separate testing questions when both are performed.
What does the reported result indicate?
It reports a probability of fluoroquinolone resistance associated with the gyrA S91F point mutation in Neisseria gonorrhoeae.
How does Medicare pay 0483U?
Medicare pays it under the CLFS at one national amount across localities and settings.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 0483U and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist